ASCO's Targeted Agent and Profiling Utilization Registry (TAPUR) Study continues to expand and now has more than 300 participants enrolled on study drug, more than 100 sites, new partnerships, and a revised protocol to lower the age of eligibility.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
The CancerLinQ Discovery™ Research & Publications Committee – the volunteer committee charged with reviewing and approving research requests utilizing data from CancerLinQ Discovery™ – will begin accepting proposals on October 1, 2017.
CancerLinQ LLC and the National Cancer Institute (NCI) have announced a partnership to facilitate the exchange of information between CancerLinQ® participating oncology practices and NCI’s Surveillance, Epidemiology, and End Results (SEER) program, one of the primary sources of data on cancer incidence and survival in the United States. The partnership aims to put valuable population-level cancer data at oncologists’ fingertips, while also strengthening the nation’s cancer surveillance efforts through a national data sharing collaboration.
CancerLinQ LLC has announced a long-term partnership with the U.S. Food and Drug Administration (FDA) that will harness cancer patient information and big data analytics to examine the real-world use of emerging and newly approved cancer therapies. Real-world data from CancerLinQ® will be used to grow the knowledge base about patterns of care across all cancer types and therapies, accelerate development of novel insights that might otherwise be challenging to obtain through standard research initiatives and data collection means, as well as potentially inform FDA regulatory strategy and decision-making processes.
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO®, and the National Comprehensive Cancer Network® (NCCN®) have announced a collaboration to provide a link to the NCCN website for easy access to the NCCN Drugs & Biologics Compendium (NCCN Compendium®) within CancerLinQ®. This resource will support CancerLinQ® physicians and provides evidence-based guidance regarding the appropriate use of drugs and biologics in patients with cancer.
Draft recommendations as part of a focused update to the ASCO/College of American Pathologists (CAP) evidence-based guideline for human epidermal growth factor receptor 2 (HER2) testing in breast cancer are now open for public comment through June 12, 2017.
ASCO has developed a “MACRA decision tree” tool to help oncology practices find precise information on their QPP participation status, and any applicable Merit-Based Incentive Payment System (MIPS) exceptions, based on practice or provider-specific information.
The American Medical Association (AMA) is the largest association of physicians and medical students in the United States. The AMA recognizes ASCO as a national speciality society, offering ASCO the ability to advocate on behalf of the oncology community. The follow ASCO in Action Brief is the first of a series that explores ASCO’s work with the AMA on behalf of the oncology community.
ASCO has announced the launch of its Center for Research & Analytics (CENTRA), which aims to make an array of cancer data available to the oncology community and provide consultation and support for research and analysis. To help guide the program, ASCO has appointed Elizabeth Garrett-Mayer, PhD, to serve as ASCO's Director of Biostatistics and Data Management division.
On June 7 at noon (ET), ASCO will host a one-hour webinar for participants to learn more about the Quality Oncology Practice Initiative (QOPI®) Certification Program.
ASCO strongly opposes the Administration’s proposed cuts to federal agencies that support biomedical research and Medicaid for Fiscal Year 2018, including a 21 percent proposed funding cut for the National Institutes of Health (NIH), a 20 percent proposed funding cut for the National Cancer Institute (NCI), and reducing Medicaid funding by more than $600 billion. Such extreme reductions to programs that are critical to research will fundamentally damage our nation’s progress in treating patients and will irreversibly harm our nation’s already fragile biomedical research infrastructure.
CancerLinQ LLC and the Society of Gynecologic Oncology (SGO) have announced a partnership where the SGO will provide expert guidance and insight on the management of gynecologic cancers for the CancerLinQ® platform. CancerLinQ LLC is a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO) that is developing and operating CancerLinQ®, a real-world, big data initiative focused on cancer patient medical information, aimed at improving the quality of patient care and outcomes.
CancerLinQ, LLC CEO, Kevin Fitzpatrick will join leaders of the cancer community including the Cancer Support Community and the American Cancer Society in speaking at the 2017 eyeforpharma Oncology Market Access & Pricing, taking place in Philadelphia.
On May 23, 2017, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA® , Merck & Co.) for adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options or with MSI-H or dMMR colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
On May 19, ASCO submitted comments to Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, on the FDA’s proposed guidance for industry on demonstrating interchangeability of biosimilars with a reference product. In ASCO’s comments to the FDA, the society took the opportunity to reiterate its strongly held position that physicians and patients should have the ability to select evidence-based treatment options – including the specific biologic product – most appropriate for the patients’ circumstance.